Fate sees pos­i­tive B-cell lym­phoma da­ta at #AS­CO21; Imag­inAb se­cures fund­ing for CD8 imag­ing tri­als

Fate Ther­a­peu­tics re­vealed some new da­ta at #AS­CO21 for their R/R B-cell lym­phoma pro­gram on Fri­day.

The San Diego biotech said in­ter­im Phase I da­ta for FT516 re­vealed eight of 11 pa­tients as of the March cut­off date had achieved an ob­jec­tive re­sponse, in­clud­ing six who hit lev­els of com­plete re­sponse. Four of the pa­tients came from the sec­ond dose co­hort, while the oth­er sev­en came from the third dose co­hort.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER